EPICOVIDEHA has received funds from Optics COMMITTM (COVID-19 Unmet Medical Needs and Associated Research Extension) COVID-19 RFP program by GILEAD Science, United States (Project 2020-8223).
The authors thank all contributors for their utmost contributions and support to the project during a pandemic situation and to Susann Blossfeld and Sebastian Rahn for her administrative and technical assistance.
LP served as the principal investigator. FM, JSG and LP contributed to study design, study supervision, and data interpretation and wrote the paper. AB, PC, MH, NK, PK, AP, FP, AOC and LP conceived the study idea. LP, JSG, and FM did the statistical plan, analysis and interpreted the data. All the authors recruited participants and collected and interpreted data. All authors contributed to manuscript writing and review of the manuscript. All authors agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
JSG has received speaker honoraria from Gilead Nordica, outside the submitted work.
AG has been consultant and advisory board member for Agios, bluebird bio, Bristol Myers Squibb, Novartis, Novo Nordisk, and has received research grants from Saniona and Sanofi, outside the submitted work.
IE has provided lectures or advisory board consultation to MSD, GILEAD, Janssen, Fundación Publica Andaluza Progreso y Salud, Grupo Español de trasplante hematopoyético y Terapia celular (GETH) and Fundación Madrileña de Hematología y Hemoterapia, outside the submitted work.
JP has received research funding from MSD, personal fees from Gilead and Pfizer and is stockholder of AbbVie Inc. and NovoNordisk, outside the submitted work.
NCB has received funding from the NIH via K23 NS110470, outside the submitted work
PK reports grants or contracts from German Federal Ministry of Research and Education (BMBF) B-FAST (Bundesweites Forschungsnetz Angewandte Surveillance und Testung) and NAPKON (Nationales Pandemie Kohorten Netz, German National Pandemic Cohort Network) of the Network University Medicine (NUM) and the State of North Rhine-Westphalia; Consulting fees Ambu GmbH, Gilead Sciences, Mundipharma Resarch Limited, Noxxon N.V. and Pfizer Pharma; Honoraria for lectures from Akademie für Infektionsmedizin e.V., Ambu GmbH, Astellas Pharma, BioRad Laboratories Inc., European Confederation of Medical Mycology, Gilead Sciences, GPR Academy Ruesselsheim, medupdate GmbH, MedMedia, MSD Sharp & Dohme GmbH, Pfizer Pharma GmbH, Scilink Comunicación Científica SC and University Hospital and LMU Munich; Participation on an Advisory Board from Ambu GmbH, Gilead Sciences, Mundipharma Resarch Limited and Pfizer Pharma; A pending patent currently reviewed at the German Patent and Trade Mark Office; Other non-financial interests from Elsevier, Wiley and Taylor & Francis online outside the submitted work.
RC has been consultant and speaker faculty to Roche, Abbvie, Janssen, Astra Zeneca, Kite, Takeda, consultant to Kyowa-Kirin, Incyte, Beigene, and has received a research grant from Pfizer, outside the submitted work.
SL has received miscellaneous support from Janssen, Gilead, Roche, Abbvie, Sanofi, Novartis, Actelion, Pfizer, some honorarium from Gilead and a research grant from Janssen, outside the submitted work.
OAC reports grants or contracts from Amplyx, Basilea, BMBF, Cidara, DZIF, EU-DG RTD (101037867), F2G, Gilead, Matinas, MedPace, MSD, Mundipharma, Octapharma, Pfizer, Scynexis; Consulting fees from Amplyx, Biocon, Biosys, Cidara, Da Volterra, Gilead, Matinas, MedPace, Menarini, Molecular Partners, MSG-ERC, Noxxon, Octapharma, PSI, Scynexis, Seres; Honoraria for lectures from Abbott, Al-Jazeera Pharmaceuticals, Astellas, Grupo Biotoscana/United Medical/Knight, Hikma, MedScape, MedUpdate, Merck/MSD, Mylan, Pfizer; Payment for expert testimony from Cidara; Participation on a Data Safety Monitoring Board or Advisory Board from Actelion, Allecra, Cidara, Entasis, IQVIA, Jannsen, MedPace, Paratek, PSI, Shionogi; A patent at the German Patent and Trade Mark Office (DE 10 2021 113 007.7); Other interests from DGHO, DGI, ECMM, ISHAM, MSG-ERC, Wiley.
The remaining authors have no disclosures to declares for this submitted paper